Viewing Study NCT00249366



Ignite Creation Date: 2024-05-05 @ 12:07 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00249366
Status: COMPLETED
Last Update Posted: 2016-04-11
First Post: 2005-11-03

Brief Title: Treatment of Alcohol Withdrawal in Hospital Patients
Sponsor: Virginia Commonwealth University
Organization: Virginia Commonwealth University

Study Overview

Official Title: Acute Drug Withdrawal in a General Medical Setting
Status: COMPLETED
Status Verified Date: 2016-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal
Detailed Description: Studies show that symptom-triggered dosing is best for treatment of alcohol withdrawal in patients on chemical dependence units without other illness On general medical hospital wards withdrawal may be affected by comorbid medical illness A clinical trial was undertaken to determine whether there is a difference between symptom-triggered ST and fixed-schedule FS dosing of lorazepam in patients hospitalized on general medical wards at a University medical center Subjects were assessed by their nurses with the Revised Clinical Institute Withdrawal Assessment for Alcohol CIWA-Ar scale Subjects in the ST arm received lorazepam doses based on CIWA-Ar score Subjects in the FS arm received scheduled lorazepam with tapering over 4 days

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
K23AA000222 NIH None httpsreporternihgovquickSearchK23AA000222